Organigram Expands into Australia with Medical Cannabis Vape and Pastille Launch

Event summary

  • Organigram launched Edison and BOXHOT medical cannabis vapes and pastilles in Australia on February 24, 2026.
  • The company introduced 10 product SKUs through a distribution partnership with Leafio, Montu Australia’s wholesale arm.
  • Products will be available to over 4,000 pharmacies via Leafio’s nationwide supply chain.
  • Organigram is also pursuing the acquisition of Sanity Group, a leading German cannabis company.

The big picture

Organigram’s expansion into Australia aligns with the growing demand for non-flower medical cannabis products, driven by consistent dosing and ease of administration. The move complements its proposed acquisition of Sanity Group, reinforcing its strategy to become a global leader in medical cannabis. The company’s focus on science-led innovation positions it to capitalize on the shift toward ready-to-consume formats in regulated markets.

What we're watching

Market Penetration
How Organigram’s non-flower products will perform in Australia’s evolving medical cannabis market.
Regulatory Dynamics
Whether Australia’s increasing approvals for medical cannabis access will sustain demand for ready-to-consume formats.
Execution Risk
The pace at which Organigram can integrate Sanity Group and expand its global footprint.